GSK plc
XETRA:GS71
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.71
20.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
GSK plc
Pre-Tax Income
GSK plc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
GSK plc
XETRA:GS71
|
Pre-Tax Income
£7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Pre-Tax Income
£7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Pre-Tax Income
$11.4B
|
CAGR 3-Years
119%
|
CAGR 5-Years
31%
|
CAGR 10-Years
21%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Pre-Tax Income
-$72.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Pre-Tax Income
$14m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Pre-Tax Income
$462m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
4%
|
|
GSK plc
Glance View
In the heart of the pharmaceutical landscape, GSK plc stands as a venerable institution that intertwines scientific discovery with patient well-being. Originally founded as GlaxoSmithKline, the company has navigated the evolving demands of healthcare with a deft blend of innovation and strategic acumen. As a major player in the global healthcare sector, GSK operates within three principal segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Each division dances to the beat of discovery and development, bringing forward medicines and vaccines that address acute and chronic health challenges ranging from respiratory illnesses to immunological disorders. This operational design not only aligns with the urgent medical needs of populations worldwide but also creates diverse revenue streams that fortify the company’s financial foundation. Delving deeper, GSK generates its income through a meticulously structured business approach. In Pharmaceuticals, it harnesses cutting-edge research and development to create novel therapies, with a strong emphasis on therapeutic areas such as HIV and oncology. The Vaccines division spearheads innovations by focusing on prophylactic solutions, producing vaccines that combat diseases like influenza and shingles, thereby playing a pivotal role in global public health initiatives. Meanwhile, the Consumer Healthcare unit offers a portfolio of brands that have become household staples, catering to wellness and everyday health needs. This multifaceted business model ensures that GSK remains resilient amidst the fluctuations of industry trends and regulatory landscapes, continually maintaining its relevance within the global healthcare sphere by advancing medicines and nurturing health through a blend of science and strategy.
See Also
What is GSK plc's Pre-Tax Income?
Pre-Tax Income
7B
GBP
Based on the financial report for Sep 30, 2025, GSK plc's Pre-Tax Income amounts to 7B GBP.
What is GSK plc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-5%
Over the last year, the Pre-Tax Income growth was 113%. The average annual Pre-Tax Income growth rates for GSK plc have been 18% over the past three years , -2% over the past five years , and -5% over the past ten years .